What's the Value of Amyris' Molecule Development Strategy?

Amyris is developing way too many molecules to keep track of, so investors should focus on its strategy instead.

Jun 18, 2014 at 12:50PM

Artemisinin-based combination therapies are some of the most important weapons wielded by the developing world against malaria, which claims over 620,000 lives each year. While artemisinin is effective, its supply and cost is greatly affected by volatile agricultural production of the world's sweet wormwood crop. Enter synthetic biology pioneer Amyris (NASDAQ:AMRS), which was founded to build a yeast strain capable of producing artemisinic acid -- converted into artemisinin with light -- through fermentation. The yeast strain was transferred to a major pharmaceutical company (link opens PDF) on a royalty-free basis in 2008 and now produces one-third of the global demand for the drug under a "no profit, no loss" principle.

Today Amyris commercially manufactures and sells just two molecules -- the renewable building block hydrocarbon farnesene and the fragrance patchouli oil -- but its engineered yeasts still replace less efficient agricultural production methods for each molecule. If two molecules doesn't sound impressive, consider that the company has at least 22 additional molecules in development under contract with global fragrances companies such as Firmenich and International Flavors & Fragrances (NYSE:IFF) . That doesn't include several more with performance material companies such as Michelin and fuels and chemicals companies such as Total (NYSE:TOT) and BASF. That presents one giant problem for investors: How can you possibly value Amyris with more than 22 molecules in development, especially if you don't know what any of them are?

Rather than focus on valuing independent molecules or the sum of the parts, investors can focus on a simpler analysis evaluating the development strategy for all new molecules. Here's how the strategy breaks down and how it affects investors.

Are all molecules pursued with the same approach?
No. Molecules under development at Amyris are organized into two categories. The first group is comprised of novel molecules, such as patchouli oil, and represents four of the molecules being actively developed at the company's facilities in San Francisco right now. Yeast strains need to be engineered to produce these molecules at commercially viable metrics (yield, productivity, and titer) to ensure they are profitable and cost-competitive from the first day of production for partners such as International Flavors & Fragrances. These are fermentation products.

G

The commercial target improvement (y-axis) of selected fermentation products is shown versus time (x-axis). Fragrance 1 is patchouli oil. Source: Amyris.

The second group is comprised of molecules derived from farnesene, such as those being developed in the recently announced commercial agreement with Takasago, and represents nine molecules on-deck in the development pipeline. These benefit from piggybacking on the strain development of farnesene for all uses -- fuels, performance materials, lubricants, cosmetics, and more -- from the start, which means their development is not dependent on fermentation of a new molecule. These are derivative products.

Do all molecules have the same commercial targets?
No. The commercial targets for each molecule are determined by the market price for the intermediate application or end market. For instance, farnesene is generally applied to lower-margin markets, which requires it to be produced at very low costs (recently below $3.50 per liter). High-value fragrance molecules can be produced profitably at much higher costs than farnesene if the market price is sufficient.

G

Amyris estimates; not drawn to scale. Source: Amyris.

As you can see, the mystery molecule that sells for $1,000 per kilogram need not be produced at ultralow costs to achieve profitability.

How does Amyris decide which molecules to target?
Amyris develops molecules based on how partners rank their molecules, which are prioritized using factors such as addressable markets, market growth, sourcing concerns and/or challenges, and pricing volatility to their supply chain. For example, molecules sourced from volatile agricultural methods that address a large market with attractive growth would take development priority for International Flavors & Fragrances over a molecule with few supply constraints that addresses a low-growth market. The latter would still be in the pipeline, but it would be a lower-priority target.

When does Amyris receive payments?
Value is created throughout the development process, which only makes it fair for payments to be received throughout the process, too. For fermentation products, partners pay Amyris for strain development and manufacturing for each molecule. A similar agreement is in place with Total for enhancing farnesene production and lowering costs, which also pays Amyris for leasing lab space and time at the pilot plant in San Francisco, as well as a deal with BASF for an undisclosed molecule. For all molecules, whether they are fermentation products or derivative products, Amyris shares in the cost benefit and performance benefit for the specific end market. That way, the company's incentives are aligned with those of the respective partner to reduce its manufacturing costs even after a molecule is produced at scale.

This payment structure is a critically important part of Amyris' development strategy, although it is poorly understood by most investors and even Wall Street analysts. Not only does it pay for the development and commercialization of products that will grow the company's top and bottom lines in the future, but it could also help the business achieve cash flow positive operations in 2014. 

Foolish takeaway
Given the number of molecules in the pipeline that will make their commercial debuts over the next seven years, investors should probably pay more attention to the company's development strategy than attempting to value the entire pipeline. The 22 molecules under development for the fragrance industry represent $1 billion in potential revenue for Amyris, which is addressable by the end of the decade if the company successfully develops two to four new commercial strains each year. That's quite impressive considering it neglects growth from performance materials, which are expected to generate up to $150 million in revenue by 2017 and upward of $320 million at full production of a new facility. Of course, the company must execute on its vision for its fledging fragrance portfolio. So far, so good; but there's a long road ahead.

Warren Buffett likes well-oiled business models
Amyris has developed a pretty good development strategy for its product portfolio, but Warren Buffett's strategy for buying companies is unbeatable. He's so confident in one company's can't-live-without-it business model, he just loaded up on 8.8 million shares. An exclusive, brand-new Motley Fool report details this company that already has over 50% market share. Just click HERE to discover more about this industry-leading stock... and join Buffett in his quest for a veritable landslide of profits!

Maxx Chatsko owns shares of Amyris. Check out his personal portfolioCAPS pageprevious writing for The Motley Fool, or his work for SynBioBeta to keep up with developments in the synthetic biology industry.

The Motley Fool recommends Total (ADR). Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers